基本信息。

B7-33 is a novel synthetic compound, originally discovered and developed by a research team at Monash University in Australia. Its development is rooted in the identification of relaxin receptor 1 (RXFP1), along with the recognition of this receptor’s tremendous potential as a therapeutic target for a wide range of diseases and conditions.

The research team led by Professor David Handelsman first synthesized B7-33 in the early 2010s. The compound was designed to develop a drug that can act specifically on the RXFP1 receptor. Subsequent in vitro and in vivo tests have demonstrated that B7-33 holds therapeutic potential for hypertension, kidney disease and heart failure. The team’s research findings on B7-33 have been published in academic journals including Journal of Biological Chemistry and Hypertension.

These research publications highlight the unique mechanism of action of this compound, as well as its potential to be developed as a therapeutic regimen for patients.

 

---

Our factory

“Strength builds the foundation, and excellent services reach all over the world.” Create win-win situation with customers